Predicted protein targets (top 5)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ABL1 | P00519 | 20/20 | 0.82 |
| ▸ | BCR | P11274 | 19/20 | 0.82 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.82 |
| ▸ | MAPT | P10636 | 1/20 | 0.82 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.82 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL16906995 | 0.92 | ABL1 (0.73) | ABL1BCRKDM4EMAPTMAPK1 | |
| SCHEMBL10013582 | 0.90 | ABL1 (1.00) | ABL1BCRKDM4EMAPTMAPK1 | |
| SCHEMBL29438984 | 0.90 | ABL1 (1.00) | ABL1BCRKDM4EMAPTMAPK1 | |
| SCHEMBL925002 | 0.90 | ABL1 (1.00) | ABL1BCRKDM4EMAPTMAPK1 | |
| SCHEMBL29936260 | 0.90 | ABL1 (1.00) | ABL1BCRKDM4EMAPTMAPK1 | |
| SCHEMBL3904982 | 0.89 | ABL1 (0.82) | ABL1BCRKDM4EMAPTMAPK1 | |
| SCHEMBL13771172 | 0.89 | ABL1 (1.00) | ABL1BCRKDM4EMAPTMAPK1 | |
| SCHEMBL25639124 | 0.87 | ABL1 (0.82) | ABL1BCRKDM4EMAPTMAPK1 | |
| SCHEMBL3450466 | 0.86 | ABL1 (0.79) | ABL1BCRKDM4EMAPTMAPK1 | |
| SCHEMBL16898350 | 0.85 | ABL1 (0.82) | ABL1BCRKDM4EMAPTMAPK1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 15 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| WO-2020198055-A1 | ALLOSTERIC BCR-ABL PROTEOLYSIS TARGETING CHIMERIC COMPOUNDS | YALE UNIVERSITY (US) | 2020-10-01 | — | — | WO | disclosed |
| US-20200297725-A1 | ALLOSTERIC BCR-ABL PROTEOLYSIS TARGETING CHIMERIC COMPOUNDS | YALE UNIVERSITY | 2020-09-24 | — | — | US | disclosed |
| US-20200297725-A1 | ALLOSTERIC BCR-ABL PROTEOLYSIS TARGETING CHIMERIC COMPOUNDS | YALE UNIVERSITY | 2020-09-24 | — | — | US | disclosed |
| WO-2018066545-A1 | HETEROCYCLIC COMPOUND | 公益財団法人ヒューマンサイエンス振興財団 | 2018-04-12 | — | — | WO | disclosed |
| US-20160031826-A1 | Substituted Heterocyclic Compounds for Treating or Preventing Viral Infections | PRESIDENT AND FELLOWS OF HARVARD COLLEGE | 2016-02-04 | — | — | US | disclosed |
| WO-2015106292-A1 | BCR-ABL TYROSINE-KINASE LIGANDS CAPABLE OF DIMERIZING IN AN AQUEOUS SOLUTION, AND METHODS OF USING SAME | COFERON, INC. (US) | 2015-07-16 | — | — | WO | disclosed |
| WO-2015106294-A1 | BIVALENT BCR-ABL TYROSINE KINASE LIGANDS, AND METHODS OF USING SAME | COFERON,INC. (US) | 2015-07-16 | — | — | WO | disclosed |
| WO-2015106294-A1 | BIVALENT BCR-ABL TYROSINE KINASE LIGANDS, AND METHODS OF USING SAME | COFERON,INC. (US) | 2015-07-16 | — | — | WO | disclosed |
| WO-2015106292-A1 | BCR-ABL TYROSINE-KINASE LIGANDS CAPABLE OF DIMERIZING IN AN AQUEOUS SOLUTION, AND METHODS OF USING SAME | COFERON, INC. (US) | 2015-07-16 | — | — | WO | disclosed |
| US-20110021524-A1 | COMPOSITIONS AND METHODS FOR TREATING CANCERS | IRM LLC (BM) | 2011-01-27 | — | — | US | disclosed |
| EP-2229217-A1 | COMPOSITIONS AND METHODS FOR TREATING CANCERS | IRM LLC (BM) | 2010-09-22 | — | — | EP | disclosed |
| WO-2009091476-A1 | COMPOSITIONS AND METHODS FOR TREATING CANCERS | IRM LLC (BM) | 2009-07-23 | — | — | WO | disclosed |
| US-7125997-B2 | Differential tumor cytotoxicity compounds and compositions | IRM LLC (BM) | 2006-10-24 | — | — | US | disclosed |
| WO-2004058713-A1 | DIFFERENTIAL TUMOR CYTOTOXOCITY COMPOUNDS AND COMPOSITIONS | IRM LLC (BM) | 2004-07-15 | — | — | WO | disclosed |
| US-20040132786-A1 | Differential tumor cytotoxicity compounds and compositions | IRM LLC, A DELAWARE LIMITED LIABILITY COMPANY (BM) | 2004-07-08 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20040132786-A1 | Differential tumor cytotoxicity compounds and compositions | MIF, FOXM1, MYADM | ABL1 1482/4885BCR 3068/4885KDM4E 4087/4885 |
| US-20110021524-A1 | COMPOSITIONS AND METHODS FOR TREATING CANCERS | ABL1, BCR, MCL1 | ABL1 1/4885BCR 2/4885KDM4E 826/4885 |
| US-20200297725-A1 | ALLOSTERIC BCR-ABL PROTEOLYSIS TARGETING CHIMERIC COMPOUNDS | BCR, ABL1, ABL2 | ABL1 2/4885BCR 1/4885KDM4E 368/4885 |
| US-20160031826-A1 | Substituted Heterocyclic Compounds for Treating or Preventing Viral Infections | HAVCR2, DDX5, DPYD | ABL1 858/4885BCR 2508/4885KDM4E 3342/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.